Dr. Blazar has made innumerable contributions to the field of transplantation immunology and stem cell biology. His research has focused on designing strategies to reduce blood and bone marrow transplant complications. His lab is currently working on developing new therapies that prevent and treat acute and chronic graft-versus-host disease (GVHD), a donor anti-host immune reaction resulting in inflammation and cell-mediated destruction (acute GVHD), or later after transplant resulting in autoimmune-like manifestations and fibrosis (chronic GVHD). Dr. Blazar’s early contributions to preventing acute GVHD included preclinical modeling of commonly used immunosuppressant drugs as well as CTLA4-Ig, a recombinant fusion protein that blocks the specific T cell immune response to host antigens. The latter recently became the first U.S. Food and Drug Administration (FDA) drug for acute GVHD prophylaxis. In more current chronic GVHD studies, he discovered that donor germinal center B cells that produce anti-host antibodies work in concert with macrophages to cause chronic GVHD. His lab’s paradigm-shifting research in preclinical chronic GVHD modeling contributed to each of the three FDA-approved chronic GVHD drugs.

Dr. Felgner’s work is rooted in biophysics, structure, and hydrodynamic properties of bilayer membranes conducted at the University of Virginia. In 1984 there were no positively charged bilayer forming lipids available in nature to prepare positively charged lipid vesicles. He collaborated with chemists at Syntex Research Institute to synthesize and characterize a series of positively charged bilayer forming lipids. When these vesicles interact with negatively charged nucleic acid the lipids and the nucleic acid reorganize together into a new structure, he called Lipoplex capturing 100% of the input nucleic acid. Lipoplexes are synthetic virus-like particles that deliver functional nucleic acid into cultured cells and ‘Lipofection’ has since become the most widely used in vitro transfection method. Felgner published highly cited reports showing functional gene transfer of plasmid DNA and mRNA into mouse muscle in vivo. This work spawned a separate field of nucleic acid vaccine science which culminated in the COVID LNP mRNA vaccines. Currently Felgner is Director of the University of California Irvine Vaccine R&D Center. There he developed a protein microarray platform to measure vaccine induced antigen specific antibody levels against thousands of individual antigens from dozens of bacteria, parasites and viruses. At the beginning of the COVID outbreak his Coronavirus Antigen Microarray was poised to measure SARS-CoV-2 mRNA vaccine induced Ab levels against dozens of respiratory virus antigens. He has 50 issued US patents, is a Fellow of the National Academy of Inventors, and recipient of the Robert Koch Award for infectious disease and vaccine science, and the Princess of Asturias Award for Technical and Scientific Research. His work chronicles a remarkable period of non-viral nucleic acid delivery and vaccine science, breaking the mRNA tabu, and culminating in the phenomenal success of mRNA vaccines important to the world today.

JorgeKalilisProfessorofClinicalImmunologyandAllergyandDirectoroftheLaboratoryofImmunologyattheHeartInstitute(InCor),SchoolofMedicine,University of São Paulo (FMUSP), Brazil. He isAdjunct Professor at the GeorgeWashingtonUniversity,DC,USA,andattheCaseWestenUniversity,Cleveland.He representsLatinAmericainthescientificadvisoryboardoftheInternationalInstituteofGeneticEngineeringand Biotechnology (ICGEB), an UNO Institutionsince 2013 and a member of the Brazilian Academy ofSciencessince1995.Since2001,hecoordinatesiii-InstituteforInvestigativeImmunology,aNationalInstitutelinkedtotheMinistryofScienceandTechnology,inBrazil.Inaddition,heco-chairstheFederationofClinicalImmunology Societies- FOCIS Centerof Excellence in São Paulo and member of the Council ofthe USP PasteurInstitute’sboardsince2018.HeismemberoftheDSMB/NIHforanalysesofphase3clinicaltrialsofvaccinesanti COVID supported by the US government and board member of COVAX, a WHO/GAVI/CEPI initiative toselecting and buying COVID vaccines to distribute to the world and member of the National Academy of Medicine and Lebanon-Brazilian Academy of Letters, Arts and Sciences.Kalil graduated in Medicine in Brazil (1977),hasaMaster’sdegreeinImmunologyandImmunogeneticsandisDoctorofScienceinHumanBiology,bothfrom the University of Paris VII, while working at Jean Dausset’s laboratory (Dr. Dausset was awarded theNobel Prize in 1980 for the discovery of HLA). He studies the mechanisms of immune recognition anddistinction of self and no self. He contributed to the understanding of T-cell allorecognition, rejection andtolerance mechanisms in organ transplantation. He was pioneer in the rethinking of antibodies and graftrejectionanddisfunction,andalsodescribedthemechanismofhowmicrobesinducebreakageoftoleranceto self, leading to autoimmune diseases in humans. He is currently developing vaccines against COVID-19Streptococcus, HIV, Dengue and Zika in advanced scientific stage. His academic production registers morethan600entriesindexedbytheWebofScienceandmorethan8,000quotations.Heistheholderofseveralpatents.KalilspentasabbaticalyearasaVisitingProfessorandCo-DirectoroftheHLAlaboratory,Department of Pathology, at the Stanford School of Medicine (1991) and was International Scholar of theHoward Hughes Medical Institute (1991-1995). He stayed one year, 2018/2019 in Boston as “DistinguishedVisiting Professor” at Harvard Medical School, Evergrande Institute of Immunological Diseases. He wasPresidentoftheHeartInstitute(InCor)(2006-2008)andalsoChairmanoftheboardofitssupportFoundationZerbini(2006-2017),DirectoroftheButantanInstituteandChairmanoftheBoardofitsFoundation(2011-2017),PresidentoftheInternationalUnionofImmunologicalSocieties(2013-2016).HewasfounderandfirstPresidentoftheBrazilianAssociationofOrganTransplantation,founderandVicePresidentof the Latin American Association of Immunology, President of the Brazilian Society of Immunology, andHead of the Department of Internal Medicine of the FMUSP. He also chaired the XIII International Congressof Immunology and was President of the International Union of Immunological Societies (IUIS) (2013-2016).He served as Special Advisor to Minister AdibJatene in the matter of immunobiologicals (1993-1995). KalilwasdecoratedbythePresidentofBrazilasCommanderandlaterwiththeGreatCrossoftheBrazilianOrderof Scientific Merit, and by the President of France as Chevalier of the National Order of Merit. Among theawards received in Brazil and abroad, Kalil received the World Award in Biology from the Academy ofSciences of the Developing Countries (TWAS) in 2005, and the Science Award of the Conrado WesselFoundation in 2011. In 2013 he received the Legislative Medal of Merit, granted by the Brazilian Congress. In2016, he received the Medal of Victory, award instituted by the Ministry of Defence to honor national andforeignpersonalitieswhoseactionscontributedtothedefenseoffreedomandworldpeace,andin2015theBiotech-SpaceAward,grantedbychoiceofabiotechnologynetworkcomposedofmorethan2,000researchers and students. He is Doctor Honoris causa by the University Pierre et Marie Curie (SorbonneUniversités, Paris, France)andfrom Universidade Federal do Rio Grande do Sul (Brazil). He hasbeennominated Fellow of the Royal College of Physicians (FRCP) and got the Honorary membership of ASTMH(2015).

KP Chang received his BS in 1965 from the Department of Entomology, National Taiwan University, Taipei, Taiwan, his M.A. in 1968 and his PhD in 1972 in Microbiology & Cell Biology from Department of Biology, Ontario State University of Guelph, Canada. He was a postdoctoral fellow in parasitology at Rockefeller University in New York City from 1972 to 1974. He held the position of research associate from 1974 through 1976, assistant professor from 1976 to 1979, and associate professor from 1979 through 1983 at Rockefeller University. He joined the faculty at Chicago Medical School in 1983 as professor of microbiology and immunology. He has held that position until now in the same discipline and the same School as a faculty member also in the Center for Cancer Cell Biology, Immunology and Infection, Rosalind Franklin University of Medicine and Science.

Dr. Lijuan Yuan is a full Professor of Virology and Immunology at the Department of Biomedical Sciences and Pathobiology at Virginia Polytechnic Institute and State University (Virginia Tech), Blacksburg, Virginia. She received a Ph.D. degree in virology and immunology at The Ohio State University, Ohio, USA in 2000. Sheestablishedherlaboratoryin 2007 at Virginia-Maryland College of Veterinary Medicine, Virginia Tech. The research in Dr. Yuan’s lab focuses on host-pathogen interactions in enteric viruses including infectivity, pathogenesis and immunity, and on intervention strategies to reduce viral diarrhea including prophylactics, therapeutics, vaccines and influences of probiotics/prebiotics and gut microbiotausing gnotobiotic pigs asmodels. Her research achievements have established her as one of a few experts in the world in developing and utilizing gnotobiotic pig models to study human enteric viruses and vaccine-induced immune responses.She has authored/co-authored 117 scientific publications, including recently a book titled “Vaccine Efficacy Evaluation: The Gnotobiotic Pig Model”. Her h-index is 41.She has graduated 7 PhD students as major advisor.She teaches lectures ofMolecular Virology to graduate students and Emerging Infectious Diseases to DVM students. She received Pfizer Award for Research Excellence in 2011, Outstanding Graduate Mentor Award from Virginia Tech Graduate School in 2017, and Grant Turnwald Innovation Award from Virginia-Maryland College of Veterinary Medicine in 2022.

MD – MedicalSchool Zagreb 1979. Pediatrician 1986., Dept. ofPediatrics, UniverstiyHospitalCenter Zagreb. Subspecialistandconsultantinpediatricallergyandclinicalimmunology 2007. PhD 2008, Universitxof Osijek, Croatia (DiagnosticInterpretationoftheResultsoftheDosimetricMethacholineBronchialChallenge Test inChildhoodAsthma). Workexperience: University HospitalCenter-Zagreb - Dept. ofPediatrics (1980 – 2003 and2008-2020). Children'sHospital Srebrnjak - Zagreb (2003 - 2008). Chief, Day Care andOutpatientServices, Dept. ofPediatrics, University HospitalCenter Zagreb (2009-2020). Mainfieldofinterest: pediatricallergyandclinicalimmunology. Authoredandco-authored more than 120 articlesinmedicaljournals, 26 chaptersin 13 medicaltextbooksin Croatian and English. Invitedlecturer on more than 150 occasionsofprofessional, academicandsponsoredlectures.. President, Croatian PediatricSociety – Zagreb (2009 - 2013). FounderandPresident, Section on PediatricAllergyandClinicalImmunology (2010 - 2020). Member: Croatian MedicalAssociation, Croatian PediatricSociety, Section on AllergyandClinicalImmunologyofthe Croatian PediatricSociety, European AcademyofAllergyandClinicalImmunology, European Society for Immunodeficiencies, Central European VaccinationAdvisoryGroup, Committee on theImplementationofDrugsintheTreatmentandProphylaxisof COVID-19 (Ministryof Health), National ImmunizationTechnicalAdvisoryGroup (NITAG - Croatian Institute ofPublic Health).

Yehuda Shoenfeld is the founder and head of the Zabludowicz Center for Autoimmune Diseases, at the Sheba Medical Center, which is affiliated to the Sackler Faculty of Medicine in Tel-Aviv University, in Israel. Professor Shoenfeld is also the Incumbent of the Laura Schwarz-Kipp Chair for Research of Autoimmune Diseases at the Tel-Aviv University. Professor Shoenfeld’s clinical and scientific works focus on autoimmune and rheumatic diseases, and he has published more than 2230 papers in journals such as New Eng J Med, Nature, Lancet, Proc Nat AcadScie, J Clin Invest, J Immunol, Blood, FASEB, J Exp Med, Circulation, Cancer and others. His articles have had over 130,000 citations.(H index 130) He has written more than 350 chapters in books, and has authored and edited 35 books, some of which became cornerstones in science and clinical practice, such as "The Mosaic of Autoimmunity", "Infections and Autoimmunity" and the textbook "Autoantibodies" , "Diagnostic criteria of autoimmune diseases",Covid,Autoimmunity and Post covid" all of which were published by Elsevier and sold thousands of copies. Professor Shoenfeldis on the editorial boards of 43 journals in the field of rheumatology and autoimmunity and is the founder and the editor of the IMAJ (Israel Medical Association Journal) the representative journal of science and medicine in the English language in Israel, and also is the founder and Editor of Autoimmunity Reviews (Elsevier) (Impact factor 17.3) and co-Editor of the Journal of Autoimmunity (Impact factor 13,3). For the past twenty years Yehuda has been the Editor of “Harefuah” – The Israel journal in medicine (Hebrew). Professor Shoenfeld received the EULAR prize in 2005, in Vienna, Austria: "The infectious etiologyof anti-phospholipid syndrome", and received a gold medal from the Slovak Society of Physicians for his contribution to Israel – Slovakia collaboration (March 2006). He is also an honorary member of the Hungarian Association of Rheumatology and the Royel Society of Physicians (UK). In UC Davis, USA, Professor Shoenfeld received the Nelson's Prize for Humanity and Science for 2008. In 2009 he was honoured as Doctoris Honoris Causa, from Debrecen University (Hungary), and from 2009 he is honorary member of the Slovenian National Academy of Sciences. He was recently awarded a Life Contribution Prize in Internal Medicine in Israel, 2012 as well as the ACR Master Award in 2013.In 2019 YS was elected for the Israeli Academy of Sciences .He acted as the President of the University Ariel(1920-1922), Professor Shoenfeld has educated a long list of students >55 becoming Professors and heads of departments and institutes. Disclosures None.

Dr. Eva Lee is the Director of the Center for Operations Research in Medicine and Homeland Security and a Distinguished Scholar in Logistics at the Data and Analytics Innovation Institute. The center focuses on biomedicine, public health, and defense, advancing domains from basic science to translational medical research; intelligent, personalized, quality, and cost-effective delivery; medical preparedness; health and homeland security; and protection of critical infrastructures. She also serves as a subject matter expert in information and enterprise systems, risks, and decisions. Prior, Dr. Lee served as theVirginia C. and Joseph C. Mello EndowedChair, and Professor in the School of Industrial and Systems Engineering at Georgia Tech, and Co-Director for theNSF-I/UCRC Center for Health Organization Transformation. From 2015 - 2018, Dr. Lee served on the National Biodefense Science Board, a 13-member federal committee that provides advice and guidance to the President of the United States, and the Secretary of U.S. Department of Health and Human Services. She was an expert scientific consultant for the Food and Drug Administration Center for Devices and Radiological Health from 2014-2018. Shehas alsoserved as the Senior Health Systems Engineer and Professor for the U.S. Department of Veterans Affairs. Dr Leeapplies combinatorial optimization, math programming, game theory and machine learning, and parallel computation to biological, medical, health systems, and logistics analyses. Her clinical decision-support systems (DSS) assist in disease diagnosis/prediction, treatment design, drug delivery, treatment and healthcare outcome analysis/prediction, and healthcare operations logistics. In logistics, she tackles operations planning and resource allocation, and her DSS address inventory control, vehicle dispatching, scheduling, transportation, telecom, portfolio investment, disaster emergency treatment response, and facility location/planning. She has received numerous practice excellence awards, including the INFORMS Franz Edelman Award on novel cancer therapeutics, the Daniel Wagner prize on vaccine immunity prediction, and the Pierskalla award on bioterrorism, emergency response and mass casualty mitigation She is a fellow at INFORMS and AIMBE. Lee has served on NAE/NAS/IOM, NRC, NBSB, DTRA panel committees related to CBRN and WMD incidents, public health and medical preparedness, and healthcare systems innovation. She holds ten patents on medical systems and devices. Her work has been featured in the New York Times, London Times, disaster documentaries, and in other venues.

▪ Dall’anno accademico 2013/2014 incaricato dell’insegnamento di “Medicina sociale” presso la Facoltà di Giurisprudenza. ▪ Membro del collegio dei docenti del dottorato in “Legal and Social Sciences” per gli anni accademici 2013/2014, 2014/2015, dal 2020/2021 a tutt’oggi ▪ Membro del collegio dei docenti del dottorato in “Law, Economy and Society” per gli anni accademici 2011/2012 e 2012/2013 ▪ Dall’anno accademico 2010/2011 incaricato dell’insegnamento di “Medicina delle assicurazioni” presso la Facoltà di Giurisprudenza ▪ Membro del collegio dei docenti del dottorato in “Law, Political and Social Sciences” per gli anni accademici 2008/2009 e 2010/2011 ▪ Dall’anno accademico 2006/2007 e sino all’anno accademico 2009/2010 incaricato dell’insegnamento di “Deontologia Medica” presso la Facoltà di Giurisprudenza ▪ Dall’anno accademico 2006/2007 incaricato dell’insegnamento di “Immunoematologia forense” presso la Facoltà di Giurisprudenza ▪ Per l’anno accademico 2006/2007 incaricato dell’insegnamento di “Medicina delle assicurazioni” presso la Facoltà di Giurisprudenza ▪ Dall’anno accademico 2005/2006 incaricato dell’insegnamento di “Elementi di legislazione sanitaria e norme di sicurezza” (SSD MED/42) presso la scuola di specializzazione in Biochimica Clinica della Facoltà di Scienze M.F.N. ▪ Dal 1° novembre 2004 professore associato confermato a tempo pieno presso la Facoltà di Giurisprudenza (settore scientifico disciplinare MED/43 “Medicina Legale”) ▪ Membro del collegio dei docenti del dottorato in “Diritto Civile nella Legalità Costituzionale” dall’anno accademico 2003/2004 all’anno accademico 2007/2008 ▪ Dal 2003 al 2005 membro del consiglio del “centro interdipartimentale di ricerca in diritto civile costituzionale” ▪ Dall’anno accademico 2001/2002 incaricato dell’insegnamento di “Criminologia” presso la Facoltà di Giurisprudenza ▪ Dall’anno 2002 al 2004 membro del consiglio direttivo e coordinatore del Master di II livello in Bioetica; dal 2004 membro del consiglio direttivo del Master di II livello in Bioetica ▪ Membro del collegio dei docenti del dottorato in “Diritto civile nella legalità costituzionale” nell’anno accademico 2000/2001 ▪ Dal primo novembre 2001 professore associato non confermato presso la Facoltà di Giurisprudenza (settore scientifico disciplinare MED/43 “Medicina legale”) ▪ Dall’anno accademico 2000/2001 all’anno accademico 2005/2006 incaricato dell’insegnamento di “Assicurazioni sociali ed infortunistica del lavoro” presso la Facoltà di Giurisprudenza ▪ Dall’anno accademico 2000/2001 incaricato dell’insegnamento di “organizzazione dei laboratori e automazione” (SSD BIO/12) presso la scuola di specializzazione in Biochimica Clinica della Facoltà di Scienze M.F.N. ▪ Dal 16 gennaio 1999 ricercatore non confermato presso la Facoltà di Giurisprudenza (gruppo F22B) ▪ Nel 1998 docente a contratto della materia “antinfortunistica” nell’ambito del Corso di specializzazione F.S.E. “Tecnico prevenzione antinfortunistica ed igiene del lavoro” ▪ Dal 1 giugno 1994 al 15 gennaio 1999 funzionario tecnico (VIII qualifica funzionale) presso l’Istituto di Medicina Legale ▪ Dal 2 gennaio 1991 al 31 maggio 1994 collaboratore tecnico (VII qualifica funzionale) presso l'Istituto di Medicina Legale ▪ Dal 1° settembre 1987, per la durata di 3 anni, ha prestato la sua opera presso l'Istituto di Medicina Legale in qualità di tecnico a contratto ai sensi dell'art. 26 del D.P.R. 382/80 ▪ Dal 1986 fa parte del Comitato di Redazione della rivista Medicina Legale Quaderni Camerti e dal 1999 è redattore della stessa rivista ▪ Dal 1986 al 1990 medico interno addetto alle esercitazioni ed alle tesi di laurea presso l'Istituto di Medicina Legale.

Kevin Brown is an authority on the history of medicine and on Alexander Fleming and the development of penicillin. A graduate of Hertford College, University of Oxford and University College, London, he is Trust Archivist to Imperial College Healthcare NHS Trust and Alexander Fleming Laboratory Museum Curator at St Mary’s Hospital, London, a museum and archives which he established. He was Chairman of the London Museums of Health and Medicine, 2001-04, and is a Trustee of the charity St Mary’s Hospital Association. He was awarded a Gladstone’s Library Scholarship for 2015. He was the first historian to deliver the Andrew Moyer lecture at the United States Department of Agriculture National Center for Agricultural Utilization Research. He is the author of Penicillin Man: Alexander Fleming and the Antibiotic Revolution (2004), and many other books and articles on the history of health and medicine. He has lectured widely in the United Kingdom, Italy, Spain, Portugal, Germany, Belgium, Switzerland and the United States

Paco Pino, PhD, is the Head of R&D at ExcellGene, based in Monthey, Switzerland. At the company, he is applying science and cutting-edge technology to support process science services. Prior to working at ExcellGene since 2018, he started working at the University of Geneva in 2007 and, in 2013, was appointed Assistant Professor at the Department of Microbiology and Molecular Medicine. Before 2013, he spent three years as a postdoc at Imperial College London, developing genetic tools to study malaria parasites. He earned his Ph.D., in cerebral malaria resulting from Plasmodium falciparum infection, from the University of Paris, France. Recently, during the COVID pandemic years, he has helped in advancing the science of SARS-CoV-2 Spike Protein; His team is involved in several vaccine development programs from molecules design to clinic, resulting in numerous peer-reviewed articles in Process, Biochemistry, Int J Mo Sci, and Spectrum.

Dr. Kuraoka is a cellular immunologist, Assistant Research Professor in Immunology at Duke University. He obtained his Ph.D. in Applied Biochemistry at the University of Tokyo, followed by postdoctoral research works at National Institutes of Infectious Diseases in Japan, and then at Duke University. He has a broad background in immunology with specific expertise and experience on B-lymphocyte biology. He developed high-throughput single B-cell culture approach to study humoral responses to infection and vaccination in mice, humans, and non-human primates. His research focuses on understanding 1) diversification of B-cell repertoire in humoral responses against vaccinations or viral infections (e.g., HIV, HSV, Influenza) and 2) regulation of B-cell development and immune tolerance in health and disease.

Rok Sekirnik graduated in Chemistry at University of Oxford, where he also completed his PhD. He has worked in the areas of mAb, vaccine and gene therapy vector development in various roles, including Principal Scientist at Novartis and Project Manager at Batavia Biosciences. His team at BIA Separations, now a Sartorius company is working on developing high yielding, cost-effective purification approaches for pDNA and mRNA production.

Francesco Paolo Bianchi was born in Putignano (Italy) on 1987, 29 October. He graduated in Medicine and Surgery at Bari School of Medicine in 2015; in 2019, he achieved post-degree in Public Health at Bari University and advanced course in Epidemiology and Biostatistics at “Cattolica” Rome University. Since May 2022, he is tenured Senior Physician at the Epidemiology Unit of Bari Policlinico General University Hospital; he is a member of Professor Silvio Tafuri’s research team at the Interdisciplinary Department of Medicine of University of Bari, as expert of biostatistics applied to epidemiology. He is author of more than 80 articles published in international scientific journals (hindex: 12) and more than 50 contributes to international and national conferences; most of scientific papers and contributes are in the field of vaccinology and prevention of infectious diseases.

Dr Md Nazmul Huda is a social epidemiologist and researcher with expertise in mixed-method research. His research projects aim to explore the intersecting health disadvantages of marginalised communities and their role in promoting the sexual, reproductive, and mental health of marginalised populations, including older people, indigenous communities, refugees, and migrant populations. Huda’s projects address health inequalities using multi-level interventions. He published 32 research articles [1 book chapter, 1 paper in Encyclopedia and 30 articles) in high-ranking international journals (BMC Psychiatry, BMC Psychology, Psychogeriatrics Journal, BMJ Global Health, Scientific Reports, BMJ Open, Frontiers in Public Health, and Human Vaccines &Immunotherapeutics), 7 media articles and 1 report. Dr Huda and his teams received grants from Western Sydney University, Green Univesit of Bangladesh, Save the Children and the University of Liberal Arts Bangladesh and Action Aid. Dr Huda obtained a PhD in Public Health and Health Sociology from the University of New South Wales, Australia. His cutting-edge PhD research facilitated a better understanding of interventions needed to solve HIV transmission problems and improve the critical population’s sexual health. Earlier, he did a Bachelor of Social Sciences (by research) and Master of Social Sciences in Sociology/Health Sociology (by research) from the University of Dhaka, Bangladesh. Dr Huda is an experienced researcher, lecturer and academic with excellent teaching evaluation by students: (94 out of 100). For example, he has worked as a full-time lecturer/senior lecturer in Health Sociology and sessional lecturer/academic in Public Health at various institutions in Australia (University of New South Wales, University of Sydney, Australian Catholic University and Southern Cross Education Institute) and Bangladesh (Green University and Independent University in Bangladesh) for nearly six years.

Dr. Amina Tebaa working since 1993 at the Centre anti poison et de pharmacovigilance of Morocco (CAPM). In charge of pharmacovigilance of vaccine since 1999 until now with a university diploma of vaccinology in France in 2000 . Head of pharmacovigilance department since 2015 until December 2022. Présidente of morroccan pharmacovigilance society between 2018-2022 member of CIOMS vaccines working group from 2015 to 2018 and member in CIOMS working group for covid 19 vaccines in 2020 member of Brighton collaboration, and scientific advisory board in the PROFORMA project since 2019 until now for strengthening the national pharmacovigilance system in East African countries . Involved in pharmacovigilance and in Pharmacovigilance of vaccines training, system assessment and developing project in collaboration with WHO , CDC, global Found and others partners.

Silvio Tafuri was born in Brindisi (Italy) on 1980, 17 August. He graduated in Medicine and Surgery at Bari School of Medicine in 2005, In 2008, he achieved post-degree in Public Health, and in 2013, he obtained a Ph.D. in Hygiene, Public Health and Food Safety. He is a consultant with the Apulian Observatory for Epidemiology in the field of vaccination strategies, surveillance of infectious diseases and adverse events following immunization. From 2014 to March 2020, he has served as Assistant Professor of Public Health at the Bari School of Medicine, and from March 2020 to April 2021, as Associate Professor of Public Health. Since April 2021, he has served as a Full Professor of Public Health. He works as a consultant in the Public Health Unit of the Policlinico Bari General Hospital, in which he is charged with the management of vaccination activities; since March 2020, he has worked as Chief of the COVID19 Control Room Unit. He is the author of 270 articles, published in international scientific journals (IF >650, h-index 26); the most of his scientific papers focus on the field of vaccinology and the prevention of infectious diseases.

Prof. Pere-Joan Cardona is chief of the Microbiology Department at the Hospital “Germans Triasi Pujol” of the Catalan Institute of Health (ICS) and Professor at the UniversitatAutònoma de Barcelona. He is a clinical microbiologist that has devoted 25 years in discerning the mechanisms that allow latent tuberculosis infection and those that lead to the development of active TB. To do so, he founded the Experimental Tuberculosis Unit at the IGTP Research Institute, developing several “in vivo” and “in silico” experimental models, which led to the invention of the RUTI therapeutic vaccine and the use of host-directed therapies against TB. He is also involved in the use of the properties of environmental mycobacteria to balance the immune response against several diseases. He has an extensive experience in leading clinical trials to address new approaches for the development of new tools in diagnosis, prophylaxis and therapy of TB, and has collaborated in several international consortiums focused on the TB study.

Dr Umema has been teaching physiology for the last 10 years.She currently works as an associate professor in the Physiology Department at Rehman Medical Institute. She has done MPhil in Physiology and is currently perusing PhD in Physiology. Dr Umema has been awarded the 2022 Research Recognition Award by American Physiological Society. She is also the Vice President of the South Asian Association of Physiologists (SAAP). Alongside teaching she has also been involved in research.She has presented at various national and international platforms and has also coauthored three books.She devised a formula for predicting height on basis of age, gender and hand size.Much of her work is on teachings ofPhysiology. To begin with she gauged the effectiveness of taking an entry test before admittance in medical school. She also conducted research on problem-based learning (PBL) system by comparing academic performance of two medical schools. The pupils of the school with PBL teaching in curriculum showed a drastic improvement in performance as they progressed. She has also been part of a mixed method research to assess the educational environment of a medical school both qualitatively and quantitatively. Another study measured the effect of handedness on academic performance and it was proved that there is no relation between the two. She has worked on elaborating the gender differences in the autonomic control of the cardiovascular system. Most recently Dr Umema has been working on developing a novel tool for gauging brain’s health.

My name is Daniel Workineh Aynew (Dr.) from East Africa, Ethiopia and I have MSc degree in Veterinary vaccinology from Pan African University Life and Earth Science Institute (PAULESI), University of Ibadan and the second MSc in Veterinary Microbiology from University of Gondar (UoG). I have considerable research experience and practical knowledge in vaccinology, virus and bacterial isolation, cell culture, standard molecular biology techniques, vaccine development, vaccine quality test and also have experience in working with laboratory animals. I also participated and certified in different trainings and workshops. In addition, I have four publications and two papers were submitted for publication.

Dr.KoustavSarkar has completed his PhD at the age of 31 years from Chittaranjan National Cancer Institute/Jadavpur University, Kolkata, India. Currently, he is the research assistant professor in department of Biotechnology, SRM Institute of Science and Technology, Chennai, India. He presented papers in more than 50 national and international conferences. Dr. Sarkar has been involved in research over the last twenty years (including a Ph.D. and three Post-Docs) and made several important contributions to the development of advanced science and technology. He was involved in understanding the molecular mechanisms of the development of human immune responses in health & disease. Dr. Sarkar has already published 46 high-impact scientific publications in internationally reputed journals. He was also co-author of four book chapters. During PhD., Dr. Sarkar has developed a process for isolating glycoprotein(s) from neem leaf, which has immunomodulatory and cancer preventive functions. One patent (Patent Number: 259434; Grant Date: 12-Mar-2014) has been granted for this invention. He found out that the neem leaf glycoprotein helped to generate carcinoembryonic antigen specific anti-tumor immune responses utilizing macrophage & dendritic cell mediated antigen presentation to T and B cells and the induction of type 1 protective immunity. To study the intricate molecular mechanisms involved in the type 1 protective immunity, Dr. Sarkar moved to USA. Research from his US laboratory was essential in revealing for the first time a novel nuclear function for a well known cytoskeleton structure associated protein, Wiskott Aldrich Syndrome Protein (WASp) in the transcriptional regulation of T helper cell 1 (Th1)-differentiation through its effect on epigenetic modifications at the T-BET gene-promoter locus. Since that time, Dr. Sarkar has been actively involved in further understanding how different biomolecules are associated to develope the protective type-1 immunity during the cancer vaccine development.